DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review hig...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2007-01, Vol.96 (2), p.189-195
Main Authors: O'CONNOR, J. P. B, JACKSON, A, PARKER, G. J. M, JAYSON, G. C
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - pharmacokinetics
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Biomarkers
Biomarkers, Tumor - analysis
Biomedical engineering
Blood
Cancer research
Cell cycle
Clinical trials
Clinical Trials as Topic
Contrast agents
Drug dosages
Humans
Magnetic resonance imaging
Magnetic Resonance Imaging - methods
Medical research
Medical sciences
Minireview
Permeability
Physiology
Tomography
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6603515